An exploratory study of plasma microRNAs related to cancer-associated thrombosis in ovarian clear cell carcinoma

The development of cancer-associated thrombosis (CAT) is related to tissue factor (TF), TF pathway inhibitor 1 (TFPI1), and TFPI2 regulated by several microRNAs (miRNAs). Therefore, we investigated the relationship between plasma miRNAs and CAT in ovarian clear cell carcinoma (OCCC). This retrospective study included 97 patients diagnosed with OCCC who underwent surgery at our institution between 2006 and 2024. Patients were categorized into two groups: those with CAT before initial treatment (CAT group) and those without CAT (non-CAT group). MiRNAs related to TF, TFPI1, and TFPI2 were selected using several miRNA databases. Plasma samples collected immediately before primary surgery were quantified using reverse transcription-quantitative polymerase chain reaction. Relative miRNA expression levels were calculated as fold-changes based on cycle threshold values between the target and control miRNAs. The comparison of miRNA levels between CAT group and non-CAT group and pairwise correlations among the candidates of miRNAs by the Bonferroni correction. CAT was identified in 23 of 97 patients (23.7%). The CAT group had more patients with advanced-stage disease, larger tumors, greater ascites volume, and higher CA125 and D-dimer levels than the non-CAT group. MiR-19b-3p, miR-20a-5p, miR-23a-3p, miR-27a-3p, miR-103a-3p, and miR-126-5p were selected from the database, and miR-19b-3p, miR-20a-5p, and miR-126-5p were significantly downregulated in the CAT group. Strong positive correlations were observed between miR-19b-3p and miR-20a-5p and among miR-23a-3p, miR-27a-3p, miR-103a-3p, and miR-126-3p. The area under the curve value of miR-19b-3p for detecting CAT was 0.788, with a sensitivity of 87.0 and a specificity of 67.6, and low miR-19b-3p levels were independently associated with CAT in the multivariable analysis (odd rate: 4.39, 95% confidence interval: 1.01–21.58, p = 0.049). Plasma miRNA levels associated with TF, TFPI1, and TFPI2 were lower in patients with OCCC and CAT. These findings might provide the insight into CAT development in OCCC.

Authors

Institutions

Publication Details

Journal
BMC Cancer
Published
2026-11-16
DOI
https://doi.org/10.1186/s12885-026-17358-4
Primary Topic
MicroRNA in disease regulation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

An exploratory study of plasma microRNAs related to cancer-associated thrombosis in ovarian clear cell carcinoma

Taira Hada, Masashi Takano, Risa Tanabe, Naohisa Kishimoto et al.
3 links
BMC Cancer
MicroRNA in disease regulation
article

An exploratory study of plasma microRNAs related to cancer-associated thrombosis in ovarian clear cell carcinoma

Taira Hada, Masashi Takano, Risa Tanabe, Naohisa Kishimoto, Yoshinobu Hamada, Hiroaki Soyama, Kohei Omatsu, Tsubasa Ito, Osamu Imamura, Soko Nishimura, Taro Miyake, Jin Suminokura, Kento Kato
article en

Abstract

The development of cancer-associated thrombosis (CAT) is related to tissue factor (TF), TF pathway inhibitor 1 (TFPI1), and TFPI2 regulated by several microRNAs (miRNAs). Therefore, we investigated the relationship between plasma miRNAs and CAT in ovarian clear cell carcinoma (OCCC). This retrospective study included 97 patients diagnosed with OCCC who underwent surgery at our institution between 2006 and 2024. Patients were categorized into two groups: those with CAT before initial treatment (CAT group) and those without CAT (non-CAT group). MiRNAs related to TF, TFPI1, and TFPI2 were selected using several miRNA databases. Plasma samples collected immediately before primary surgery were quantified using reverse transcription-quantitative polymerase chain reaction. Relative miRNA expression levels were calculated as fold-changes based on cycle threshold values between the target and control miRNAs. The comparison of miRNA levels between CAT group and non-CAT group and pairwise correlations among the candidates of miRNAs by the Bonferroni correction. CAT was identified in 23 of 97 patients (23.7%). The CAT group had more patients with advanced-stage disease, larger tumors, greater ascites volume, and higher CA125 and D-dimer levels than the non-CAT group. MiR-19b-3p, miR-20a-5p, miR-23a-3p, miR-27a-3p, miR-103a-3p, and miR-126-5p were selected from the database, and miR-19b-3p, miR-20a-5p, and miR-126-5p were significantly downregulated in the CAT group. Strong positive correlations were observed between miR-19b-3p and miR-20a-5p and among miR-23a-3p, miR-27a-3p, miR-103a-3p, and miR-126-3p. The area under the curve value of miR-19b-3p for detecting CAT was 0.788, with a sensitivity of 87.0 and a specificity of 67.6, and low miR-19b-3p levels were independently associated with CAT in the multivariable analysis (odd rate: 4.39, 95% confidence interval: 1.01–21.58, p = 0.049). Plasma miRNA levels associated with TF, TFPI1, and TFPI2 were lower in patients with OCCC and CAT. These findings might provide the insight into CAT development in OCCC.

BMC Cancer
National Defense Medical College Hospital (JP), National Defense Medical College (JP)
Good health and well-being
MicroRNA in disease regulation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon